EN DE
Watch Diagnostic Medical Systems SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Diagnostic Medical Systems SA (ALDMS) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Diagnostic Medical Systems SA stock €0.69, price €0.92, that is 24.7% below the price, quality 32 out of 100. Rating: overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0012202497

DM Diagnostic Medical Systems SA logo Some data Nov 3, 2026

Diagnostic Medical Systems SA

ALDMS · PA
Expensive, weak quality

Our calculation puts a fair price 25% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +9.2 %/yr in EUR)
Thin margins · 0.9% net margin (TTM)
Some data
Fair value €0.6900 · Overvalued
Quality 32/100
Negative free cash flow
Trails peers (2/11)
Narrow moat 30/100 · thin data
Watch Diagnostic Medical Systems SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€1.52 €0.6800 Fair Value €0.6900 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range €0.6800 – €1.52 · fair‑value band €0.6000 – €0.8000 · the €0.9160 price screens above the €0.6900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 3, 2026.

Follow Diagnostic Medical Systems in your weekly email

Every Wednesday you see whether Diagnostic Medical Systems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France.

Show moreShow less

The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and long leg exams.

It also provides mobiles under the !M1, ONYX, Rafale/Rafale DR, and !Mobile Wall Stand names; c-arm products under the EVO R+ FP ADAM and EVO + / EVO R+ names; retrofit kits; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.

Stock analysis

Diagnostic Medical Systems SA (ALDMS) currently trades at €0.9160, while our model-based Fair Value estimate is €0.6900, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €0.7700 per share, and 1 of the 5 models we run sit above the €0.9160 price.

Bear case: the Earnings-Based group reads lowest at €0.6900, and 4 of the 5 models stay below the price. Data coverage for this calculation is medium.

Scenario range: €0.6000 (bear) to €0.8000 (bull), the price of €0.9160 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Diagnostic Medical Systems SA reported revenue of €50.0M in FY2025 versus €36.3M in FY2021, a compound +8.4%/yr. Reported net income was −€167K in FY2025.

Key figures

Market cap €26.8M Micro · P/E ratio 45.8 · P/S ratio 0.52 · EPS (TTM) €0.0200 · Net margin 0.9% · Return on equity 4.5% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin 4.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −25%, ALDMS screens richer than that median.

Fair Value models

Bear €0.6000 Fair Value €0.6900 Bull €0.8000
Price €0.9160 · Downside -24.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0172 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV €0.6000 €0.6900 €0.7700 74
ROIC Compounder €0.6000 €0.6900 €0.8000 72
EV/EBITDA €1.26 €1.83 €2.40 67
All 5 models by family
Earnings-Based
EPV €0.6000 €0.6900 €0.7700 74
Multiples
EV/EBIT €0.4600 €0.7700 €1.07 64
EV/EBITDA €1.26 €1.83 €2.40 67
EV/Revenue €0.2000 €0.4800 €0.7600 50
Economic Profit
ROIC Compounder €0.6000 €0.6900 €0.8000 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 73
Does it invest with discipline instead of growing at any price?
Low Volatility 74
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Start year 2020 (pandemic). Over 10 years: +3.2% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.5% (2020) → 3.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALDMS screens overvalued: fair value 25% below the price. Compare with Abbott Laboratories, →

Compare Diagnostic Medical Systems SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 319 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −24.7% · Below median
Profitability
Return on equity (12 months) 4.5% · Above median
Return on assets −0.3% · Below median
Net margin (12 months) 0.9% · Below median
Operating margin (12 months) 4.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) −5.8% · Bottom 25%
Balance sheet
Debt / equity 0.35× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 45.8× · Priciest 25%
P/B 1.40× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.52× · Cheapest 25%
EV/EBITDA 21.2× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)18 · sector 17
HEALTH (low debt)83 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs ALDMS
Stryker Corporation SYK $325.87 $358.46 +10% vs ALDMS
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs ALDMS
DexCom, Inc DXCM $79.41 $87.35 +10% vs ALDMS
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs ALDMS
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs ALDMS
Siemens Healthineers AG SHL €43.16 €34.51 −20% vs ALDMS
Abbott Laboratories, ABT $109.93 $75.28 −32% vs ALDMS
Medtronic plc MDT $101.80 $65.61 −36% vs ALDMS
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs ALDMS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Diagnostic Medical Systems SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Diagnostic Medical Systems SA Fair Value". https://www.fairvalue-calculator.com/stock/ALDMS

Frequently asked questions

Is Diagnostic Medical Systems SA (ALDMS) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of €0.6900 versus a price of €0.9160, about 25% lower (overvalued).
What is the fair value of ALDMS?
Our model-based fair value for Diagnostic Medical Systems SA is €0.6900 (as of Nov 3, 2026), built from audited fundamentals. The current price: €0.9160.
What is the quality score of ALDMS?
Diagnostic Medical Systems SA has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diagnostic Medical Systems SA (ALDMS)?
Our model-based price target is the fair value of €0.6900 (as of Nov 3, 2026) from 5 valuation models. Cautious scenario €0.6000, optimistic scenario €0.8000. It is a calculation from audited fundamentals, not an analyst target.
What is the Diagnostic Medical Systems SA stock forecast for 2026?
Our models put fair value at €0.6900, about 25% lower versus a price of €0.9160 (overvalued). Cautious scenario €0.6000, optimistic scenario €0.8000. The calculation is refreshed regularly with new filings.
What is the revenue of Diagnostic Medical Systems SA (ALDMS)?
Diagnostic Medical Systems SA reported trailing-twelve-month revenue of about €51.4M (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Diagnostic Medical Systems SA (ALDMS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diagnostic Medical Systems SA it is €0.6900 per share (as of Nov 3, 2026), against a price of €0.9160. It is the blended result of 5 valuation models in 3 families (Earnings-Based, Multiples, Economic Profit).
Is Diagnostic Medical Systems SA stock overvalued or undervalued in 2026?
As of Nov 3, 2026, ALDMS trades above its calculated fair value: price €0.9160, fair value €0.6900, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALDMS?
No. The price is what the market pays today (€0.9160); the fair value is what the company's own numbers justify (€0.6900). For Diagnostic Medical Systems SA the two are €0.2260 per share apart. That gap is exactly why we show both numbers side by side.
How much is Diagnostic Medical Systems SA worth?
The market values Diagnostic Medical Systems SA at about €26.8M (market capitalisation, as of Nov 3, 2026). Per share that is €0.9160; our models calculate a fair value of €0.6900 per share.
What do the bullish and bearish scenarios say about ALDMS?
Our models span a range for Diagnostic Medical Systems SA: cautious scenario €0.6000, base €0.6900, optimistic €0.8000 per share (as of Nov 3, 2026, price €0.9160). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALDMS?
Diagnostic Medical Systems SA trades at a price-to-earnings ratio of 45.8 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.6900 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 81.8 (the reported result was a loss). Other multiples: P/B 1.4, P/S 0.5, EV/EBITDA 21.2.
How solid is the balance sheet of Diagnostic Medical Systems SA (ALDMS)?
Balance-sheet figures for Diagnostic Medical Systems SA (as of Nov 3, 2026): return on equity 4.5%, debt of 0.35 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ALDMS from its 52-week high?
Diagnostic Medical Systems SA trades at €0.9160, about 38% below its 52-week high of €1.47 and 5% above the low of €0.8700 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €0.6900 is for.
Which stocks are comparable to Diagnostic Medical Systems SA?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diagnostic Medical Systems SA stock attractive at the current price?
The data as of Nov 3, 2026: price €0.9160, calculated fair value €0.6900 (−25%), Quality Score 32/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALDMS calculated?
We run Diagnostic Medical Systems SA through 5 models from 3 families: Earnings-Based, Multiples, Economic Profit. Every model gets the same audited fundamentals; the fair value of €0.6900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Diagnostic Medical Systems SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diagnostic Medical Systems SA (ALDMS)?
The closing price on Nov 9, 2026 was €0.9160. Our model-based fair value is €0.6900, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diagnostic Medical Systems SA right now?
The price sits above even our optimistic bull case (€0.8000). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Diagnostic Medical Systems SA

How large is the market capitalisation of Diagnostic Medical Systems SA (ALDMS)?
The market capitalisation of Diagnostic Medical Systems SA is €26.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diagnostic Medical Systems SA (ALDMS)?
The price-to-sales ratio of Diagnostic Medical Systems SA is 0.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Diagnostic Medical Systems SA (ALDMS)?
Earnings per share at Diagnostic Medical Systems SA are €0.0200 (price ÷ EPS = P/E 45.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Diagnostic Medical Systems SA (ALDMS)?
The net margin of Diagnostic Medical Systems SA is 0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diagnostic Medical Systems SA (ALDMS)?
The return on equity (ROE) of Diagnostic Medical Systems SA is 4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diagnostic Medical Systems SA (ALDMS)?
On an EBIT basis the return on assets of Diagnostic Medical Systems SA is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diagnostic Medical Systems SA (ALDMS)?
The operating margin of Diagnostic Medical Systems SA is 4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diagnostic Medical Systems SA (ALDMS)?
Revenue at Diagnostic Medical Systems SA is growing −5.8% versus a year earlier (3y avg +12.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Diagnostic Medical Systems SA (ALDMS) generate?
The free cash flow of Diagnostic Medical Systems SA is −€3.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Diagnostic Medical Systems SA (ALDMS) carry?
The net debt of Diagnostic Medical Systems SA is €11.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Diagnostic Medical Systems SA in the live analysis

One click puts Diagnostic Medical Systems SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.